Suppr超能文献

BAUSSS生物标志物改善黑色素瘤生存风险评估。

BAUSSS biomarker improves melanoma survival risk assessment.

作者信息

Dixon Anthony J, Steinman Howard K, Nirenberg Alexander, Zouboulis Christos C, Sladden Michael, Popescu Catalin, Anderson Stuart, Longo Caterina, Thomas J Meirion

机构信息

Australasian College of Cutaneous Oncology, Docklands, Victoria, Australia.

American Osteopathic College of Dermatology, Kirksville, Missouri, USA.

出版信息

J Eur Acad Dermatol Venereol. 2025 Apr;39(4):865-870. doi: 10.1111/jdv.20292. Epub 2024 Aug 31.

Abstract

BACKGROUND

The American Joint Committee on Cancer (AJCC) method of staging melanoma is dated and inaccurate. It ignores important prognostic melanoma features, especially the patient's age. BAUSSS is more accurate in determining survival risk for primary cutaneous melanoma patients who have no clinical or imaging evidence of nodal or distant metastases. BAUSSS is an algorithm incorporating analysis of Breslow thickness, Age, Ulceration, Subtype of melanoma, Sex and Site. These are the six features from the patient history along with the details from the melanoma pathology report that are most predictive of mortality outcome.

OBJECTIVE

To develop a single-page document that allows the clinician to determine BAUSSS biomarker-predicted prognosis in consultation with the patient.

METHOD

From various data sources, we developed an algorithm to predict melanoma mortality using the BAUSSS biomarker system. The single-page algorithm was made available to download at https://globalmelanoma.net/bausss-survival-chart, thus being readily available without charge to all clinicians and their patients.

RESULTS

BAUSSS method of determining melanoma prognosis is more accurate and less costly than the AJCC staging system. The only surgery the patient requires is wide local excision of the primary tumour. This method of ascertaining melanoma risk does not require added surgery, costs, hospitalization, tests and anaesthesia, such as would be required if sentinel lymph node biopsy was undertaken. BAUSSS can be a useful tool in determining which primary melanoma patients are at sufficiently high risk to be considered for adjuvant drug therapy.

CONCLUSIONS

We encourage clinicians to download and print in colour this single-page BAUSSS mortality prediction tool, laminate it, and use it face to face with the patient in consultations. Not only will the patient be able to recognize his/her long-term prognosis but will also be able to see how their tumour severity compares with others.

摘要

背景

美国癌症联合委员会(AJCC)的黑色素瘤分期方法过时且不准确。它忽略了重要的黑色素瘤预后特征,尤其是患者的年龄。对于没有临床或影像学证据表明有淋巴结或远处转移的原发性皮肤黑色素瘤患者,BAUSSS在确定生存风险方面更为准确。BAUSSS是一种算法,纳入了对 Breslow厚度、年龄、溃疡、黑色素瘤亚型、性别和部位的分析。这些是患者病史中的六个特征,以及黑色素瘤病理报告中的细节,它们最能预测死亡结果。

目的

开发一份单页文件,使临床医生能够在与患者协商时确定BAUSSS生物标志物预测的预后。

方法

我们从各种数据来源开发了一种使用BAUSSS生物标志物系统预测黑色素瘤死亡率的算法。该单页算法可在https://globalmelanoma.net/bausss-survival-chart上下载,所有临床医生及其患者均可免费轻松获取。

结果

BAUSSS确定黑色素瘤预后的方法比AJCC分期系统更准确且成本更低。患者所需的唯一手术是对原发性肿瘤进行广泛局部切除。这种确定黑色素瘤风险的方法不需要额外的手术、费用、住院、检查和麻醉,而如果进行前哨淋巴结活检则需要这些。BAUSSS可以作为一种有用的工具,用于确定哪些原发性黑色素瘤患者风险足够高,需要考虑进行辅助药物治疗。

结论

我们鼓励临床医生下载并彩色打印这份单页BAUSSS死亡率预测工具,进行覆膜处理,并在与患者会诊时面对面使用。患者不仅能够了解自己的长期预后,还能看到自己的肿瘤严重程度与其他人相比如何。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验